To describe seizure outcomes and tolerability after PER administration in pediatric patients with AE-related seizures and epilepsy, highlighting the significance of this study due to limited existing data.
Key Findings:
In the ASSAE group, 42.8% of patients achieved seizure resolution during the acute phase (3 out of 7).
In the AAE group, 57.1% of patients achieved a ≥ 50% reduction in seizure frequency at the 3-month endpoint (4 out of 7).
42.8% of patients in the AAE group achieved seizure freedom at the 3-month endpoint (3 out of 7).
No serious adverse events were reported in either group.
Interpretation:
Seizure improvement was observed in some pediatric patients with AE-related seizures or epilepsy after PER administration, without serious adverse events, suggesting potential for clinical application.
Limitations:
Small sample size limits the generalizability of findings.
Most patients received concomitant ASMs and immunotherapy, complicating the attribution of outcomes to PER.
Retrospective nature may introduce biases affecting the results.
Conclusion:
Findings should be interpreted as preliminary and hypothesis-generating, indicating a need for further research to validate these results.
